Biom’up announced the coming availability of its leading product, HEMOBLASTTM Bellows, in Spain, as well as the achievement of a key milestone towards its introduction and reimbursement in the important Australian market. The company has signed the first distribution agreement ever for HEMOBLAST Bellows to cover the key Spanish market, in exclusivity with Palex Medical, a leading medical device distributor in the Iberian Peninsula. Based in Barcelona and Madrid, Palex, through its comprehensive sales network covering Spain’s main hospitals, will allow the use of HEMOBLAST Bellows in a wide range of surgical procedures, such as cardiac surgery, general and abdominal surgery and orthopedic surgery. After market tests earlier this year, the first shipment is due at the end of 2018 and the official market launch is expected in the first quarter of 2019. The Spanish market for topical hemostats is one of the largest in the European Union, estimated to have reached €75m and growing at 5% annually (source: Grand View Research), making this agreement an important commercial breakthrough for the company. Biom’up is also making substantial progress in Australia where the company has submitted a reimbursement dossier for HEMBOLAST Bellows in the Prostheses list. This dossier comes in addition to the regulatory submission for approval of the product, which was initially filed on March 15th, 2018. The final decision of the Australian authorities is expected in the first half of 2019. To prepare for the launch of HEMOBLAST Bellows in the Australian market, the Company is already in advanced negotiations with one of the leading independent medical device distributors in the country.